RNAC
NASDAQ · Biotechnology
Cartesian Therapeutics Inc
$6.36
-0.53 (-7.63%)
Financial Highlights (FY 2026)
Revenue
3.26M
Net Income
-151,703,098
Gross Margin
—
Profit Margin
-4,658.6%
Rev Growth
-70.7%
D/E Ratio
0.28
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -5,127.1% | -4,614.4% | 2.7% | 2.7% |
| Profit Margin | -4,658.6% | -4,425.7% | 2.6% | 2.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.26M | 11.10M | 132.93M | 135.85M |
| Gross Profit | — | — | 80.14M | 81.90M |
| Operating Income | -166,976,419 | -512,197,604 | 3.54M | 3.60M |
| Net Income | -151,703,098 | -465,346,926 | 3.48M | 3.56M |
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -5,127.1% | -4,614.4% | 2.7% | 2.7% |
| Profit Margin | -4,658.6% | -4,425.7% | 2.6% | 2.6% |
| Rev Growth | -70.7% | -70.7% | -1.8% | +9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 21.01M | 21.01M | 76.99M | 61.16M |
| Total Equity | 75.07M | 75.07M | 89.31M | 77.96M |
| D/E Ratio | 0.28 | 0.28 | 0.86 | 0.78 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -163,511,434 | -529,433,750 | 5.52M | 5.23M |
| Free Cash Flow | — | — | 2.68M | 1.65M |